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Abstract Cardiac magnetic resonance imaging (CMR) is a
new robust versatile non-invasive imaging technique that
can detect global and regional myocardial dysfunction,
presence of myocardial ischaemia and myocardial scar
tissue in one imaging session without radiation, with superb
spatial and temporal resolution, inherited three-dimensional
data collection and with relatively safe contrast material.
The reproducibility of CMR is high which makes it
possible to use this technique for serial assessment to
evaluate the effect of revascularisation therapy in patients
with ischaemic heart disease.
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Introduction
Ischaemic heart disease, despite advances of detection
and treatment, remains the leading cause of morbidity
and mortality in the Netherlands and more accurate
detection and evaluation of coronary atherosclerosis
may further reduce adverse outcome. Cardiac magnetic
resonance imaging (CMR) is a new robust versatile non-
invasive imaging technique that can detect global and
regional myocardial dysfunction, presence of myocardial
ischaemia and myocardial scar tissue and has the
advantage that it can evaluate all these parameters in
one imaging session without the need for ionising
radiation and with the use of relatively safe contrast
material. CMR has demonstrated a high interstudy
reproducibility which makes it possible to use this
technique for serial assessment in an individual patient
to evaluate the effect of treatment. The different
diagnostic possibilities of CMR in patients with ischae-
mic heart disease will be discussed with the focus on the
strengths and weaknesses of each particular feature.
CMR for assessment of left ventricular function
CMR is a precise and highly reproducible technique to
assess left ventricular (LV) function, volume and mass
with a lower intraobserver, interobserver, and interstudy
variability [1, 2] as compared with LV angiography or
echocardiography [3–5]. CMR is currently considered the
standard of reference for these parameters and is frequent-
ly used as a surrogate endpoint in clinical trials [6, 7].
These measurements are obtained using dynamic imaging
where a series of parallel short-axis images is acquired
covering the whole ventricle from the atrioventricular
transition to the apex. The long-axis images of both the
two- and four-chamber views in the end-diastolic phase at
end-expiration provide the reference images to acquire a
series of short-axis images (Fig. 1). To estimate LV
functional volume and mass, the Simpson method is used
where the volume of each individual slice is calculated and
added [8]. Even though the Simpson’s method has been
the standard method of CMR LV analysis for many years,
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variability in LV measurements is still present. Sources of
variability are inconsistency in planning of the images
during acquisition and post-procedure analysis, when the
annalist has to indicate the most upper and lower border of
the left ventricle. Integrating the contours of the long-axis
to short-axis contours significantly reduces interstudy
variability of all LV functional parameters and may be
the preferred analysis method (Fig. 2) [1].
Using CMR the left ventricle can be studied in detail
(Fig. 3) and even thin structures such as the heart valves
and papillary muscles can be visualised. A regular heart
rhythm and consistent breath holding are essential for
highly detailed imaging as each dynamic loop is acquired
during a 10–12 s period of suspended breathing. When
patients cannot hold their breath or have an irregular heart
rhythm, image quality may be poor and is often not good
enough for accurate analysis due to respiratory motion or
mistriggering of the ECG. In these cases real-time
dynamic acquisition without breath holding can be
performed and each image is acquired during a single
heartbeat. A disadvantage of this technique is the lower
spatial and temporal resolution which may hamper precise
LV analysis [9].
CMR for the detection of ischaemia
If a treadmill electrocardiography test for the identification
of ischaemia is physically impossible or the test is
inconclusive, non-invasive perfusion imaging may be
indicated. CMR is the latest addition to the spectrum of
non-invasive myocardial perfusion or wall motion imaging
modalities. The advantage of CMR over other technologies
is its high resolution and contrast-to-noise ratio. The two
main CMR methods for the assessment of myocardial
ischaemia are high-dose dobutamine stress test with wall
motion assessment and first pass myocardial perfusion
under pharmacological stress with adenosine. The patient
should be closely monitored during stress CMR by
measuring blood pressure and heart rhythm during infusion
of these pharmacological stressors. One must keep in mind
that the ST-segment deviation is disturbed in the static
Fig. 1 The end-diastolic image
of the two and four chamber
image (upper part) is used to
position a stack of short-axis
images (bottom) from basal to
apical with a slice thickness of
8 mm
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magnetic field and detection of ischaemia by ECG
monitoring is not possible.
High-dose dobutamine stress with wall motion assessment
During dobutamine infusion, similar to echocardiography,
functional imaging is used to detect the ischaemia-
induced wall motion abnormalities at increasing doses
from 10, 20, 30 and 40 μg/kg/min every 3 min at each
stress level and imaging is repeated at every stress level
in both long- and short-axis orientations. It is important
to closely monitor the development of wall-thickening
abnormalities and if these develop the test is considered
positive for a haemodynamically significant coronary
stenosis. In a meta analysis of the pooled data of 13
publications investigating 735 patients using dobutamine
stress CMR for the detection of ischaemia, sensitivity
was 83% (95% CI 79–88%) and specificity 86% (95%
CI 81–91%) when analysed on a per-patient level [10].
Nagel et al. compared dobutamine stress CMR with
dobutamine stress echocardiography in patients with
suspected coronary artery disease [11]. They found that
dobutamine stress CMR had a higher diagnostic perfor-
mance. The sensitivity increased from 74 to 86% and
specificity increased from 70 to 86% (both p<0.05) using
coronary angiography as the standard of reference. Also in
Fig. 3 This is a four-chamber view of a 64-year-old patient, with a recent history of a myocardial infarction, complicated by a pseudo aneurysm
(arrow) of the anterolateral wall (end-diastolic phase, a; end-systolic phase, b)
Fig. 2 Illustration of the
method using the information
of the long axis to achieve left
ventricular volumes mass and
function. During the end-
diastolic phase (a, c), slice 1 is
partially included in the LV
volume, slice 2 is totally in-
cluded based on the long axis
areas, while during systole
(figure b, d) 0% is included of
slice 1 and slice 2 is only
partially included. At the apex,
slice 3 is partially included for
both phases (a, b, c and d) in
LV functional assessment. By
integrating the long axis and
thereby more accurately
indicating left ventricular
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patients with a poor acoustic echo window, image quality of
CMR was able to detect the presence of coronary artery
disease with a sensitivity varying from 75 to 92% depending
on the extent of coronary artery disease and a specificity of
83% using quantitative coronary angiography as standard of
reference [12].
Although CMR is a relatively new technology, it has
proven prognostic value; patients with inducible ischaemia
were at higher risk of developing a myocardial infarction or
cardiac death independent and incremental to the presence of
conventional risk factors for coronary arteriosclerosis [13].
Adenosine-stressed first-pass myocardial perfusion
Myocardial perfusion imaging is based on the changes of
myocardial signal intensity during the first passage of a
contrast bolus of intravenously injected contrast agent into
the myocardium at rest and during stress using adenosine as
a pharmacological stressor. Flow limiting coronary stenosis
during stress causes less perfusion of the subtended
myocardium than myocardium that is supplied by normal
vessels. This is visualised on CMR images as a darker
myocardial area (less perfusion, less contrast) during stress
as compared with normal perfused myocardial areas.
Perfusion of the myocardium can be assessed visually
(perfusion present or absent) or quantitatively by calculating
the myocardial perfusion reserve index [14].
The MR Impact trial [15], a multicentre multivendor
prospective trial, compared perfusion CMR with single
photon emission tomography (SPECT) and concluded that
perfusion CMR in the entire study population was superior
to SPECT. The superior sensitivity and specificity of stress
perfusion CMR is most likely due to the better spatial
resolution as compared with SPECT. In addition, SPECT is
hampered by its radiation exposure and attenuation artifacts
that sometimes make it difficult to correctly interpret the
scans. Visual assessment of perfusion images, as in the MR-
Impact trial, by experienced readers has adequate diagnostic
accuracy, but this simple approach is not always sufficient and
subtle differences may be missed as might be needed for
follow-up examination or to evaluate therapeutic effects on
myocardial perfusion. Quantitative analysis is more objective;
it also has the advantage that in patients with three-vessel
disease, balanced perfusion defects can be detected.
To determine the myocardial perfusion reserve index for
quantitative assessment, the relative upslope of a given
segment during stress is divided by the relative upslope of a
given segment at rest [16, 17]. Relative upslope is defined
as the maximum upslope of the signal intensity curve
divided by the maximum upslope of the LV cavity curve.
A disadvantage of perfusion CMR is the fact that the
investigation is cumbersome, time-consuming and acquisi-
tion and interpretation of images requires extensive expe-
rience. In a meta analysis of 14 studies of 1183 patients,
pooled data analysis showed a sensitivity of 91% (95% CI
88–94) and a specificity of 81% (95% CI 77–85) for
adenosine perfusion CMR on a per-patient level compared
with coronary angiography as standard of reference [10].
Two more recent studies showed the same diagnostic
accuracy (Table 1) [18, 19].
CMR for the assessment of viability
LV dysfunction may be the result of viable or non-viable
dysfunctional myocardium. The latter may not recover after
revascularisation therapy while viable myocardium in
patients with chronic ischaemic heart disease will recover in
weeks, months or years after revascularisation. Viable
myocardium is associated with repetitive transient ischaemia
or persistently reduced myocardial blood flow, so-called
hibernating myocardium, which must be distinguished from
permanently damaged infarcted myocardium. Viable dysfunc-
tional myocardium is defined as recovery of regional
myocardial dysfunction after revascularisation. CMR viability
assessment is achieved using low-dose dobutamine as a
functional response to examine contractile reserve or late
gadolinium enhancement as necrosis imaging or simply
assessing end-diastolic wall thickness.
End-diastolic wall thickness was the first parameter to be
used as a viability parameter prior to late gadolinium
enhancement and an end-diastolic wall thickness of <5.5 mm
represented non-viable tissue [20–22].
Low-dose dobutamine
Dobutamine is known to stimulate the β-receptors of the
myocytes, increases the ATP and oxygen consumption and
therefore improves contraction. The presence of contractile
reserve during low-dose dobutamine, which is tested at two
different doses (5 and 10 μg/kg/min), has a higher
predictive accuracy as compared with the end-diastolic
wall thickness (91 vs. 79% for preserved wall thickness)
[23]. With current fast CMR techniques, one is able to scan
the left ventricle at both stress levels and a useful approach
Table 1 Sensitivity and specificity of perfusion MRI
Author [ref#] N Sensitivity (%) Specificity (%)
Gebker [19] 455 91 70
Klem [18] 136 84 88
Nandalur [10] 1183 91 81
Schwitter [15] 234 85 67
N = number of patients
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is to acquire three short-axis views and three long-axis views
within four breath holds during each stress level. An example
of a patient with contractile reserve during dobutamine in a
region perfused by a chronic total occlusion is presented in
Fig. 4.
CMR late gadolinium enhancement
Contrast late enhancement CMR allows visualisation of the
distribution of myocardial scarring in post-infarction
patients [24–29]. Kim et al. [24] were the first to show
that delayed enhancement strongly predicts functional
improvement after revascularisation. In segments with no
infarction the likelihood of recovery was high, 78% of the
segments recovered after revascularisation while only one
segment with >75% infarct transmurality improved.
Delayed enhancement images are acquired 10–20 min
after administration of a gadolinium-based contrast agent.
The resulting image will show normal myocardium as black
and infarcted myocardium as white (Fig. 5). In acute
myocardial infarction, the contrast agent passively diffuses
into the intracellular space because the membrane is
ruptured while chronic myocardial infarction contains
collagenous material replacing the myocytes which
increases the extracellular space causing increased contrast
concentration and thus enhancement on delayed imaging
CMR [30]. Gadolinium itself is toxic but when chelated to
other molecules can be safely administered to most patients.
Fig. 5 Short-axis delayed enhancement image (a) with a subendo-
cardial infarct in the lateral wall between the white arrows. A two-
chamber delayed enhancement image with a transmural infarction of
the anterior wall between arrows (b). RV, right ventricle; LV, left
ventricle; LA, left atrium
Fig. 4 A three-chamber view in
the end-diastolic phase (a) and
the end-systolic phase (b) at rest
of a patient with an old anterior
wall infarction and a chronic
total coronary occlusion of the
left anterior descending artery,
and a three-chamber view of the
same patient after administration
of low-dose dobutamine in the
end-diastolic phase (c) and the
end-systolic phase (d) where an
improvement in contractility
was detected in the anteroseptal
wall. LA, left atrium; A, aorta;
LV, left ventricle
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However, in patients with severe kidney disease gadolinium-
based contrast agents may increase the risk of developing a
rare and potentially fatal condition known as nephrogenic
systemic fibrosis. It involves the formation of excess fibrous
connective tissue in the skin, eyes, joints and body organs.
Symptoms may include stiffness, hardening and tightening of
the skin. If body organs are involved it eventually leads to
death. The Federation of Food and Drug Administration
(FDA) advises not to use this agent in patients with acute
kidney injury or chronic, severe kidney disease (with a
glomerular filtration rate <30 ml/min/1.73m2).
When to assess functional improvement of viable
myocardium after revascularisation?
Initial studies examining the functional recovery of revas-
cularised viable myocardium were performed at 6 months
after revascularisation. It was assumed that this time period
was sufficient for the processes underlying restoration of
dysfunctional myocardium. However, we hypothesised that
it may require longer for recovery and we examined
patients at 6 months and again at 3 years of follow-up
[31]. Improvement in segments with a small subendocardial
infarction (a transmural extent of infarction of <25%) was
observed at 6 months and further improvement occurred
at 3-year follow-up. In segments with more extensive
scarring, a transmural extent of infarction between 25–
75%, improvement was only observed at 3-year follow-up
but not at 6 months.
Non-ischaemic heart disease
Abnormal enhancement may also be present in patients
with other myocardial diseases such as myocarditis,
infiltrative cardiomyopathy such as amyloidosis or Fabry’s
disease, hypertrophic cardiomyopathy or tumours. The
enhancement pattern in these patients is different from the
enhancement pattern seen in patients with a myocardial
infarction, where it usually involves the endocardium and
may extend to the epicardium and is linked with a specific
coronary vessel territory. In patients with non-ischaemic
heart disease, enhancement patterns are different and vary
between mid-myocardial enhancement, a more patchy
multifocal distribution or epicardial enhancement. Myocar-
dial contraction may also be impaired in these regions [30].
Conclusion
CMR is considered to be the standard of reference for the
comprehensive assessment of the left ventricle that can
measure cardiac function, detect ischaemia and has the
ability to assess viable myocardium in one imaging session
without the use of ionising radiation. However, in patients
with stable anginal symptoms, anatomical information of
the coronary vessel is also required for clinical decision-
making. CMR falls short for adequately visualising the
coronary artery and improvements are highly desirable to
achieve complimentary anatomical and functional informa-
tion in one investigational session.
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